Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Two hundred years of cancer research.

Literature DB >> 22646510

Two hundred years of cancer research.

Vincent T DeVita¹, Steven A Rosenberg.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2012 PMID： 22646510 PMCID： PMC6293471 DOI： 10.1056/NEJMra1204479

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

× No keyword cloud information.

42 in total

1. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid.

Authors: J D WATSON; F H CRICK
Journal: Nature Date: 1953-04-25 Impact factor: 49.962

2. Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors: Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal: Science Date: 2006-08-31 Impact factor: 47.728

3. STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III.

Authors: O T Avery; C M Macleod; M McCarty
Journal: J Exp Med Date: 1944-02-01 Impact factor: 14.307

4. RNA-dependent DNA polymerase in virions of RNA tumour viruses.

Authors: D Baltimore
Journal: Nature Date: 1970-06-27 Impact factor: 49.962

5. RNA-dependent DNA polymerase in virions of Rous sarcoma virus.

Authors: H M Temin; S Mizutani
Journal: Nature Date: 1970-06-27 Impact factor: 49.962

6. Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors: V T Devita; A A Serpick; P P Carbone
Journal: Ann Intern Med Date: 1970-12 Impact factor: 25.391

7. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

Authors: B Fisher; P Carbone; S G Economou; R Frelick; A Glass; H Lerner; C Redmond; M Zelen; P Band; D L Katrych; N Wolmark; E R Fisher
Journal: N Engl J Med Date: 1975-01-16 Impact factor: 91.245

8. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

Authors: W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters
Journal: N Engl J Med Date: 1990-09-20 Impact factor: 91.245

9. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.

Authors: B Fisher; J Costantino; C Redmond; E Fisher; R Margolese; N Dimitrov; N Wolmark; D L Wickerham; M Deutsch; L Ore
Journal: N Engl J Med Date: 1993-06-03 Impact factor: 91.245

10. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.

Authors: B Fisher; S Anderson; C K Redmond; N Wolmark; D L Wickerham; W M Cronin
Journal: N Engl J Med Date: 1995-11-30 Impact factor: 91.245

79 in total

1. Supportive/palliative care in cancer patients: quo vadis?

Authors: Jean Klastersky; Isabelle Libert; Bénédicte Michel; Myriam Obiols; Dominique Lossignol
Journal: Support Care Cancer Date: 2015-10-14 Impact factor: 3.603

2. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.

Authors: Albert A De Vera; Pranav Gupta; Zining Lei; Dan Liao; Silpa Narayanan; Qiuxu Teng; Sandra E Reznik; Zhe-Sheng Chen
Journal: Cancer Lett Date: 2018-11-01 Impact factor: 8.679

Review 10. Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.

Authors: Maria Rita Dionísio; André Mansinho; Catarina Abreu; Joana Cavaco-Silva; Sandra Casimiro; Luís Costa
Journal: Br J Clin Pharmacol Date: 2019-02-16 Impact factor: 4.335

Two hundred years of cancer research.

1. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid.

2. Cancer regression in patients after transfer of genetically engineered lymphocytes.

3. STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III.

4. RNA-dependent DNA polymerase in virions of RNA tumour viruses.

5. RNA-dependent DNA polymerase in virions of Rous sarcoma virus.

6. Combination chemotherapy in the treatment of advanced Hodgkin's disease.

7. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

8. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

9. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.

10. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.

1. Supportive/palliative care in cancer patients: quo vadis?

2. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.

Review 3. The role of Chinese medicine in clinical oncology.

4. The polymorphism (Gln261Arg) of 12-lipoxygenase and cancer risk: a meta-analysis.

Review 5. Psychoneuroimmunology and cancer: a decade of discovery, paradigm shifts, and methodological innovations.

6. [Patients in radiotherapy].

7. Clinical significance of immunotherapy with combined three kinds of cells for operable colorectal cancer.

Review 8. Use of Cyclodextrins in Anticancer Photodynamic Therapy Treatment.

9. Application of albumin-based nanoparticles in the management of cancer.

Review 10. Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.